Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Advanced Malignancies
NCT02650986Phase 2Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2017
- Primary completion
- Mar 2021
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TGFbDNRII-transduced autologous tumor infiltrating lymphocytes in melanoma, ovarian carcinoma, primary peritoneal carcinoma (PPC), fallopian tube carcinoma (PFTC), synovial sarcoma (SS), sponsored by Roswell Park Comprehensive Cancer Center. Started Jul 2017; status: active, not recruiting.
02
Drugs
TGFbDNRII-transduced autologous tumor infiltrating lymphocytes
03
Conditions
melanomaovarian carcinomaprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT02650986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650986.